Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26639
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKuzich, James A-
dc.contributor.authorKankanige, Yamuna-
dc.contributor.authorGuinto, Jerick-
dc.contributor.authorRyland, Georgina-
dc.contributor.authorMcBean, Michelle-
dc.contributor.authorWong, Eric-
dc.contributor.authorKoldej, Rachel-
dc.contributor.authorCollins, Jenny-
dc.contributor.authorWesterman, David-
dc.contributor.authorRitchie, David-
dc.contributor.authorBlombery, Piers-
dc.date2021-05-24-
dc.date.accessioned2021-05-31T22:59:17Z-
dc.date.available2021-05-31T22:59:17Z-
dc.date.issued2021-10-
dc.identifier.citationBone Marrow Transplantation 2021; 56(10): 2582-2590en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26639-
dc.description.abstractIdentification of patients at risk of initial & recurrent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant (alloSCT) may help guide prophylactic strategies. T-cell receptor beta (TRB) deep sequencing was used to identify and enumerate the T-cell repertoire harbouring TRB sequences with annotated specificity to CMV (pubCMVrep), as well as the overall T-cell receptor (TCR) repertoire diversity at day +30 & day +60 post-alloSCT for 65 patients. T-cells harbouring TRB sequences with annotated specificity for CMV were identifiable in all patients. 56% of patients required CMV treatment and 23% of the cohort developed recurrent CMV. PubCMVrep size at day +30 was not associated with reactivation, however amongst patients with antecedent CMV viremia a low day +60 pubCMVrep was associated with a greater incidence of recurrent CMV (75% vs. 21%, HR 6.16, 95% CI 1.29-29.40, P = 0.0008). Moreover, patients with high pubCMVrep only developed recurrent CMV in the setting of GVHD. Low TCR diversity at day +30 was associated with a greater incidence of initial CMV reactivation (71% vs. 22%, HR 5.39, 95% CI 1.70-17.09, p = 0.0002). pubCMVrep and TCR diversity are promising biomarkers to identify patients at risk of initial & recurrent CMV who may benefit from novel prophylactic strategies.en
dc.language.isoeng-
dc.subjectT cell receptoren
dc.subjectallogeneic stem cell transplanten
dc.subjectcytomegalovirusen
dc.titleT cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection.en
dc.typeJournal Articleen
dc.identifier.journaltitleBone Marrow Transplantationen
dc.identifier.affiliationClinical Haematologyen
dc.identifier.affiliationDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationClinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australiaen
dc.identifier.affiliationACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australiaen
dc.identifier.doi10.1038/s41409-021-01354-2en
dc.type.contentTexten
dc.identifier.orcid0000-0002-3657-8010en
dc.identifier.orcid0000-0002-1627-8934en
dc.identifier.pubmedid34031553-
local.name.researcherWong, Eric
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Nov 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.